

(c) designating the pre-selected substance as allergenic based on detecting release of mast cell and/or basophil cell mediators.

45. A method according to claim 44, wherein the cell-line is sensitized prior to said exposing.

46. A method according to claim 44, wherein the cell-line is not sensitized prior to said exposing.

47. A method according to claim 44, wherein said cell-line is a high-secretor variant which when exposed to a pre-selected substance results in at least 3-45% mediator release.

48. A method according to claim 44, wherein said cell-line is a secretor variant of RBL-2H3.

49. A method according to claim 44, wherein said cell-line is pre-incubated with a marker.

50. A method according to claim 49, wherein the marker is tritiated 5-hydroxytryptamine, or histamine or β hexoseaminidase.

51. A method according to claim 49, wherein the marker is ^{14}C arachadonic acid.

52. A method according to claim 49, wherein the method comprises exposing said cell-line to a chromogen which changes color as a result of the presence of an immunogenic reaction

53. A method according to claim 45, wherein the method comprises exposing said cell-line to an radioimmunoassay means for measuring release of mediators.